Evidence for the elimination of viral hepatitis B and C in Egypt: Results of a nationwide survey in 2022

Abstract

AbstractIntroductionViral hepatitis C (HCV) and B (HBV) were at the top of Egypt's most significant public health challenges, with an estimated 14.7% of its population having antibodies to HCV in 2008. Egypt issued an ambitious action plan in 2014 to eliminate viral hepatitis through strengthening infection control and improving patient care. In 2018, an extensive HCV mass screening campaign was conducted for the entire country's population with treating more than 4 million patients with antivirals. This study aimed to evaluate the current prevalence of viral hepatitis in Egypt after all these efforts.MethodsA cross‐sectional household cluster survey was conducted in all 27 Egyptian governorates to obtain a representative sample of Egypt's population. Subjects aged 1–70 years were interviewed using a standardised questionnaire that included demographics, viral hepatitis knowledge, previous infection and risk factors data. Laboratory testing was performed for all subjects for anti‐HCV and HBsAg using chemiluminescence. Subjects positive for anti‐HCV were further tested for HCV‐RNA by RT‐PCR. Prevalence rates were calculated by demographic groups and compared to the demographic health survey 2015 results.ResultsOf 20 881 subjects interviewed, 48.8% were males, 20.2% were children <15 years of age, and 53.7% were residents of rural areas. Of all subjects, 92 (0.4%) were HCV‐infected, 1577 (7.6%) were anti‐HCV positive and 177 (0.8%) were HBV‐chronically infected, including one patient who had mixed HBV and HCV current infection. The prevalence of HCV‐current and HBV chronic infections decreased by 93% and 20%, respectively, compared to 2015.ConclusionsEgypt achieved the elimination of the viral hepatitis goal. To maintain low rates of viral hepatitis, community health education, in addition to maintaining infection control and blood safety programs, is essential.